Regeneron begins late-stage trial of its coronavirus antibody cocktail
Category: #health  By Saipriya Iyer  Date: 2020-07-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regeneron begins late-stage trial of its coronavirus antibody cocktail

Renowned American biopharmaceutical company, Regeneron Pharmaceuticals, has reportedly announced that it has started late-stage clinical trials of its proprietary antibody cocktail to assess its effectiveness in treating and preventing COVID-19.

According to reliable reports, the news of the company’s announcement has sent its shares up by nearly 4%. The trial, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will test the proposed treatment’s ability to effectively prevent infection in individuals that have had a close exposure to a coronavirus patient.

The also company stated that the antibody cocktail has been entered into middle-to-late-stage trial phase of two separate trials to test its overall effectiveness in non-hospitalized and hospitalized coronavirus patients.

The New York based biopharmaceutical form is among some of the few front-runners that have initiated human trials to test their respective experimental therapies against the coronavirus, including AbbVie, Eli Lilly, and Gilead Sciences.

In June, Regeneron started the human clinical trial for the antibody cocktail, as a potential treatment for the novel coronavirus, with adaptive design that would allow it to quickly move to effectively include several thousands of COVID-19 patients. The late-stage clinical trial would be carried out across approximately 100 different sites and is expected to enroll more than 2,000 coronavirus patients within the U.S. The trial would follow a safety assessment that was developed for the cocktail under an early-stage clinical trial that was led by an independent committee.

For the record, the immune system creates antibodies, which are proteins that recognize, bind, and effectively neutralize viruses that are invading the body. The company’s antibody cocktail is a mix of an antibody that was made by Regeneron as well as another antibody that was isolated from coronavirus patients that have recovered. The cocktail is specifically designed to effectively bind these antibodies to the spike protein of the coronavirus.

Meanwhile, the company, in collaboration with Sanofi, was also testing the effectiveness of Kevzara, its rheumatoid arthritis medicine to treat coronavirus. However, recently this effort failed to fulfil the primary goal set by a U.S. study that is testing it in COVID-19 patients that are the most critically ill.

Source credit: https://www.cnbc.com/2020/07/06/regeneron-begins-coronavirus-antibody-cocktail-late-stage-trial.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...